HomeMedia ContactsFAQContact
Browse Media Lists

NeuroX1 Inc. and Everlum Bio Inc. have established a co-development partnership focused on accelerating the pre-clinical development of small molecule therapeutics

NeuroX1 Inc. and Everlum Bio Inc. Announce a Partnership to Develop Novel Small-Molecule Therapeutics for Rare and Neglected Pediatric Diseases.

AUSTIN, Texas, Jan. 4, 2024 NeuroX1 Inc. and Everlum Bio Inc. have established a co-development partnership focused on accelerating the pre-clinical development of small molecule therapeutics. This collaboration aims to address a broad spectrum of neurological disorders, encompassing both widespread and rare conditions. The partnership leverages NeuroX1 Inc.'s expertise in AI-powered drug discovery and neurotherapeutics in conjunction with Everlum Bio Inc.'s specialization in personalized medicine. This strategic alliance underscores the commitment of both companies to pioneering research and represents a significant milestone in the advancement of the biotech industry in Central Texas.

"Joining forces with Everlum Bio Inc. represents a pivotal step in our mission to revolutionize neurological drug discovery," said Max Dordevic, CEO of NeuroX1 Inc. "Our AI-driven platform Chiron, when integrated with Everlum's in vitro expertise, will enhance our ability to address the unmet needs in neurology, particularly for rare and neglected diseases."

Joining forces with Everlum Bio Inc. represents a pivotal step in our mission to revolutionize neurological drug discovery.

Rick Barkley, CEO of Everlum Bio Inc., added, "This partnership with NeuroX1 Inc. is a testament to our commitment to advancing neurological therapeutics, particularly in the area of rare pediatric neurological diseases. By leveraging Chiron and our proprietary in vitro platform, we are poised to make significant strides in developing effective treatments for some of the most challenging neurological conditions."

About NeuroX1 Inc.

NeuroX1 Inc. is a biotechnology company based in Austin, Texas, specializing in AI-enabled drug discovery. Its platform, Chiron, uses physics-based generative chemistry to design novel therapeutics for neurological conditions. NeuroX1's approach aims to streamline the drug development process, reduce costs, and bring eQective treatments to market faster.

About Everlum Bio Inc.

Everlum Bio Inc., also based in Austin, Texas, is a biotech company focused on personalized medicine and known for its expertise in in vitro platform technologies and translational science. The company specializes in developing and validating innovative therapeutic solutions, with a focus on rare and neglected neurological diseases. Everlum Bio Inc. is dedicated to bridging the gap between discovery and clinical application.

For More Information, Please Contact:

NeuroX1 Inc. Email: [email protected]

Everlum Bio Inc. Email [email protected]

Forward-Looking Statements

This press release contains forward-looking statements regarding the partnership's future plans and expected outcomes. These statements are based on current expectations and are subject to risks and uncertainties. Actual results may differ materially due to various factors, including but not limited to, technological challenges, regulatory hurdles, and market conditions.